Experimental lymphoma pill shows promise but trial halted early
NCT ID NCT03779113
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 27 times
Summary
This early-stage study tested an oral drug called HMPL-523 in 69 adults with lymphoma that had returned or stopped responding to standard treatments. The goal was to check the drug's safety and find the right dose. The trial was stopped early, but researchers looked at side effects and how well the drug worked in some patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aarhus University Hospital
Aarhus, Denmark
-
Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII)
Bergamo, Bergamo, 24127, Italy
-
Azienda Socio Sanitaria Territoriale di Monza (Presidio San Gerardo)
Monza, Italy
-
CHU Clermont Ferrand - Hôpital d'Estaing
Clermont-Ferrand, France
-
CHU Poitiers - Hôpital la Milétrie
Poitiers, France
-
Clinical Research Alliance
New Hyde Park, New York, 11042, United States
-
Fundacion Jimenez Diaz
Madrid, Spain
-
Groupe Hospitalier Pitie-Salpetriere
Paris, France
-
Helsingin yliopistollinen keskussairaala
Helsinki, 00029, Finland
-
Hospital Universitari Vall d'Hebron
Barcelona, Spain
-
Hospital Universitario Infanta Leonor
Madrid, Spain
-
Hospital Universitario Quironsalud Madrid
Madrid, Spain
-
Hospital Universitario Ramon y Cajal
Madrid, 28034, Spain
-
Hospital Universitario Virgen Macarena
Seville, Spain
-
Hospital Universitario Virgen del Rocio
Seville, Spain
-
Hôpital Henri Mondor
Créteil, France
-
ICO Badalona - Hospital Universitari Germans Trias i Pujol
Barcelona, Spain
-
Innovative Clinical Research Institute
Downey, California, 90241, United States
-
Institut Català d'Oncologia
Barcelona, Spain
-
KO-MED Centra Kliniczne
Biała Podlaska, Poland
-
Leo Jenkins Cancer Center/ECU School of Medicine
Greenville, North Carolina, 27834, United States
-
MD Anderson Cancer Centre
Madrid, Spain
-
Nasz Lekarz Przychodnie Medyczne
Torun, Poland
-
Ospedale San Raffaele
Milan, Milano, 20132, Italy
-
Pacific Cancer Medical Center, Inc.
Anaheim, California, 92801, United States
-
Renovatio Clinical
The Woodlands, Texas, 77380, United States
-
Summit Medical Group
Florham Park, New Jersey, 07932, United States
-
Tampereen yliopistollinen sairaala
Tampere, 33520, Finland
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza Radeckiego
Wroclaw, 50566, Poland
-
Uniwersyteckie Centrum Kliniczne
Gdansk, Poland
-
Ventura County Hematology-Oncology Specialists
Oxnard, California, 93030, United States
Conditions
Explore the condition pages connected to this study.